Anthony D Kang Selected Research

ON012380

2/2005

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony D Kang Research Topics

Disease

1	Syphilis 08/2020
1	Infections 01/2018
1	Neoplasms (Cancer) 01/2008
1	Leukemia 02/2005
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2005
1	Philadelphia Chromosome 02/2005
1	Myeloid Leukemia (Leukemia, Myelocytic) 06/2004

Drug/Important Bio-Agent (IBA)

1	ReaginsIBA 08/2020
1	AminoglycosidesIBA 01/2018
1	apramycinIBA 01/2018
1	Protein Isoforms (Isoforms)IBA 02/2005
1	bcr-abl Fusion ProteinsIBA 02/2005
1	Imatinib Mesylate (Gleevec)FDA Link 02/2005
1	ON012380IBA 02/2005
1	ElementsIBA 06/2004
1	Interleukin-6 (Interleukin 6)IBA 06/2004

Therapy/Procedure

1	Therapeutics 01/2008